# A Study of Mirikizumab in Participants With Plaque Psoriasis

> **NCT03718884** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 29 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Drug Cocktail
- **DRUG:** Mirikizumab

## Key facts

- **NCT ID:** NCT03718884
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2019-10-28
- **Final completion:** 2019-10-28
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718884, "A Study of Mirikizumab in Participants With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03718884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*